The Value of Next-Generation Sequencing in Clinical Oncology
Size does matter. Provide the level of care you would want for your own loved ones.
Please join a panel of experts for a discussion about using next-generation sequencing (NGS), tumor mutational burden (TMB) and microsatellite instability (MSI) testing to determine the most effective therapeutic options in three case studies. The size and composition of the NGS gene panel impacts an accurate assessment of TMB and the ability to identify the most actionable and effective therapeutic choices.
Tuesday, December 6, 2016
2:00-3:00 p.m. PT
3:00-4:00 p.m. MT
4:00-5:00 p.m. CT
5:00-6:00 p.m. ET
Registration and Location
Online Event | Register at bit.ly/tbDec2016
EXPERT PANEL (see back for bios)
Charles Fuchs, MD, MPH, Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute
Stephen Hodi, Jr., MD, Director of the Melanoma and Immuno-Oncology Centers at Dana-Farber Cancer Institute
Howard McLeod, PharmD, Medical Director of the Personalized Medicine Institute, Moffitt Cancer Center
Stephen Lyle, MD, PhD, Vice President of Clinical Services and Laboratory Director at KEW, Inc.
CRC: a rare ERC1-RET translocation was identified. Regorafenib is approved for CRC and targets pathways upregulated in tumors with RET translocations. The patient has recurrence of the tumor in the brain and is getting ready for surgery which will be followed by regorafenib.
MSI: a CRC patient with MSI-High and a BRAF V600E mutation which is targetable by regorafenib. BRAF mutant CRC may be resistant to anti-EGFR therapy. PIK3R1, PTEN, TP53, RNF43 and AXIN2 mutations were also detected and clinical trials are available. Learn how MSI-High tumors might be candidates for immuno-oncology drugs based on recent data.
TMB: a cutaneous squamous cell carcinoma in which CANCERPLEX identified mutations in the TP53, STK11, CDKN1B and CDKN2A/B genes as well as high tumor mutational burden. Based on this result, the physician treated the patient with an immune checkpoint inhibitor and has achieved impressive response.